KLKamolwish Laoprasopwattana

Kamolwish Laoprasopwattana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kamolwish Laoprasopwattana has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcome of Dengue Hemorrhagic Fever–Caused Acute Kidney Injury in Thai Children

    by Kamolwish Laoprasopwattana, Pornpimol Pruekprasert, Pornsak Dissaneewate, Alan Geater, Prayong Vachvanichsanong


  • Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide

    by Kamolwish Laoprasopwattana, Pornsak Dissaneewate, Prayong Vachvanichsanong

    A knowledge of the causes and risk factors of fatal infection in childhood lupus nephritis (LN) patients treated with intravenous cyclophosphamide (IVCY) is important to enable optimal treatment. During an 11-year period (1996–2007), severe infection cases occurred in 31/84 (36.9%) patients with 64 infection episodes in our central referral institution in southern Thailand. Fatal infections occurred in 13/31 (41.9%) patients, most (11/13, 84.6%) during the first infective episode. The major causative organisms of the fatal infections were fungus and Gram-negative bacilli. Fatal infections were more likely to occur in patients with a prior history of treatment with pulse methylprednisolone and in patients with more active LN, as evidenced by the higher proteinuria and serum creatinine levels and lower hemoglobin and lymphocyte counts in this group than in patients with non-fatal infections. Multivariate analysis indicated that factors associated with fatal infection were prior treatment with pulse methylprednisolone [odds ratio (OR) 11.2, 95% confidence interval (CI) 1.9–61.0], renal failure (OR 5.9, 95% CI 1.0–34.8), and fungal infection (OR 23.9, 95% CI 1.9–298.2). Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.


  • CLINICAL OUTCOME OF FEBRILE NEUTROPENIA IN CHILDREN WITH CANCER USING CEFTAZIDIME AND AMINOGLYCOSIDES

    by Kamolwish Laoprasopwattana, Pornpimol Pruekprasert, Vichai Laosombat, Malai Wongchanchailert

    To determine treatment outcome using ceftazidime–aminoglycosides in febrile neutropenic children with cancer, the authors conducted a prospective cohort study in 216 episodes. Early and complete responses to antibiotics were 108/216 (50.0%) and 133/216 (61.6%) episodes, respectively. Death, a modification of antibiotic(s), and resistance to ceftazidime were 2/118 (1.7%), 73/216 (33.8%), and 4/216 (1.9%) episodes, respectively. Primary bacteremia and emerging bacteremia during treatment were 20/216 (9.3%) and 5/216 (2.3%) episodes. Ceftazidime–aminoglycosides was found to be a reasonable initial treatment of febrile neutropenia in the authors’ institution. Imipenem is considered in patients who have clinical sepsis and who fail to respond to initial treatment.